Literature DB >> 30443683

Alternative switching strategies based on regimens with a low genetic barrier: do clinicians have a choice nowadays?

Jesús Troya1,2, Pablo Ryan3,4, Rocío Montejano5, Alfonso Cabello6, Guillermo Cuevas3, Mariano Matarranz3, Irene Cañamares3, Javier Solís3, Luis Álvarez-Sala Walther4,7.   

Abstract

Clinicians sometimes use switching strategies based on regimens such as RAL + ABC/3TC or RPV + ABC/3TC in order to resolve tolerability or safety issues associated with conventional recommended first-line strategies. Despite the low genetic barrier of these regimens, high safety and efficacy rates have been reported in retrospective studies.

Entities:  

Keywords:  Abacavir/lamivudine; Efficacy; Raltegravir; Rilpivirine; Safety; Switching

Mesh：

Substances：

Year:  2018        PMID： 30443683     DOI： 10.1007/s10096-018-3429-x

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  20 in total

1.  Raltegravir and Abacavir/Lamivudine in Japanese Treatment-Naïve and Treatment-Experienced Patients with HIV Infection: a 48-Week Retrospective Pilot Analysis.

Authors:  Akihito Suzuki; Yuki Uehara; Mizue Saita; Akihiro Inui; Hiroshi Isonuma; Toshio Naito
Journal:  Jpn J Infect Dis       Date:  2015-05-12       Impact factor: 1.362

2.  Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial.

Authors:  Jose R Arribas; Gilles Pialoux; Joseph Gathe; Giovanni Di Perri; Jacques Reynes; Pablo Tebas; Thai Nguyen; Ramin Ebrahimi; Kirsten White; David Piontkowsky
Journal:  Lancet Infect Dis       Date:  2014-06-05       Impact factor: 25.071

3.  Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.

Authors:  François Raffi; Hans Jaeger; Eugenia Quiros-Roldan; Helmut Albrecht; Elena Belonosova; Jose M Gatell; Jean-Guy Baril; Pere Domingo; Clare Brennan; Steve Almond; Sherene Min
Journal:  Lancet Infect Dis       Date:  2013-09-25       Impact factor: 25.071

4.  Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.

Authors:  Esteban Martínez; María Larrousse; Josep M Llibre; Felix Gutiérrez; Maria Saumoy; Antonio Antela; Hernando Knobel; Javier Murillas; Juan Berenguer; Judit Pich; Ignacio Pérez; José M Gatell
Journal:  AIDS       Date:  2010-07-17       Impact factor: 4.177

5.  Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir.

Authors:  Brian J Kirby; Ann C Collier; Evan D Kharasch; Dale Whittington; Kenneth E Thummel; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2011-03-15       Impact factor: 3.922

6.  Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.

Authors:  Hans-Jürgen Stellbrink; Chloe Orkin; Jose Ramon Arribas; Juliet Compston; Jan Gerstoft; Eric Van Wijngaerden; Adriano Lazzarin; Giuliano Rizzardini; Herman G Sprenger; John Lambert; Gunta Sture; David Leather; Sara Hughes; Patrizia Zucchi; Helen Pearce
Journal:  Clin Infect Dis       Date:  2010-10-15       Impact factor: 9.079

7.  Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?

Authors:  E Fontas; F van Leth; C A Sabin; N Friis-Møller; M Rickenbach; A d'Arminio Monforte; O Kirk; M Dupon; L Morfeldt; S Mateu; K Petoumenos; W El-Sadr; S de Wit; J D Lundgren; C Pradier; P Reiss
Journal:  J Infect Dis       Date:  2004-03-02       Impact factor: 5.226

8.  Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study).

Authors:  Massimiliano Fabbiani; Annalisa Mondi; Manuela Colafigli; Gabriella D'Ettorre; Francesca Paoletti; Alessandro D'Avino; Nicoletta Ciccarelli; Letizia Sidella; Rita Murri; Serena Fortuna; Vincenzo Vullo; Roberto Cauda; Andrea De Luca; Simona Di Giambenedetto
Journal:  Scand J Infect Dis       Date:  2013-10-28

9.  Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial.

Authors:  Thomas A Rasmussen; Danny Jensen; Martin Tolstrup; Ulla S Nielsen; Erland J Erlandsen; Henrik Birn; Lars Østergaard; Bente L Langdahl; Alex L Laursen
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

10.  Predicted savings to the UK National Health Service from switching to generic antiretrovirals, 2014-2018.

Authors:  Andrew Hill; Teresa Hill; Sophie Jose; Anton Pozniak
Journal:  J Int AIDS Soc       Date:  2014-11-02       Impact factor: 5.396
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.